Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679051 | 0.80 | TNKS (0.43) | AVPR1ANPY5RCYP2D6 | |
| SCHEMBL4621110 | 0.80 | AVPR1A (0.41) | AVPR1ACYP2D6 | |
| SCHEMBL4621637 | 0.80 | AVPR1A (0.50) | AVPR1A | |
| SCHEMBL8256600 | 0.80 | TRPA1 (0.38) | AVPR1ANPY5RHSD11B1CYP2D6 | |
| SCHEMBL4621149 | 0.75 | SIGMAR1 (0.45) | AVPR1ASIGMAR1HSD11B1CYP2D6 | |
| SCHEMBL2359488 | 0.75 | NPY5R (0.48) | AVPR1ANPY5R | |
| SCHEMBL4643814 | 0.72 | BRD4 (0.50) | AVPR1ACYP2D6 | |
| SCHEMBL316202 | 0.72 | TRPA1 (0.41) | AVPR1ACYP2D6 | |
| SCHEMBL315782 | 0.72 | CNR1 (0.54) | AVPR1A | |
| SCHEMBL314945 | 0.71 | OPRM1 (0.47) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | claimed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1885713-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 193/4885SIGMAR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.